{‘She possesses zero expertise’: this American healthcare community braces for Dr. Høeg's tenure at the Food and Drug Administration.

Given that America continues making historic changes to its vaccination recommendations, one figure appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid vaccines throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Program

Agency leaders had intended to unveil sweeping changes to the pediatric vaccination calendar recently, aligning the US with the Danish immunization schedule, according to reports – a major change that would place the US at odds with much of the international standard with insufficient data for public health gain. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Dr. Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing specific childhood shot schedules in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

So far comments, she has kept her attention on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in medication creation, oversight or leadership, which has been typical for previous directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who ran the center have had.”

This division has an vast portfolio at the agency, the former commissioner stated.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and all of those need to be managed,” Dr. Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a substantial management component to the position, which oversees over 5,000 staff members. “It’s a huge management job, if you execute it properly,” she added.

Agency Reaction and Controversial Programs

In response to concerns about Høeg’s credentials and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “concerns rely on incorrect presumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson explained, citing the months Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed expedited drug-approval program that reportedly concerned her former heads. “By what process are these medications being selected for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of secrecy going on at the agency right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, with the exception of vaccines.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if concerning, history, Howard said. She released a research paper using unverified public submissions to estimate the rate of myocarditis after COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are more dangerous than they are.

Included in her “desired changes” for the current federal leadership included changing guidelines for new vaccines and ending “optional” immunizations, she said following the vote on a podcast. At the FDA, Høeg has allegedly proposed barring young men from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her conclusions and reverse-engineers to accommodate the evidence in a highly disingenuous, fraudulent way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined fellow dissenters, {like|